Longboard Pharmaceuticals’ Post

Did you know, CBG may offer support to those with Parkinson's symptoms by interacting with the endocannabinoid system and potentially providing neuroprotective properties? Individual responses may vary, and more research is needed to fully understand CBG's role in supporting Parkinson's, but preclinical and clinical evidence demonstrate promising results. While research is in the early stages, it is crucial to stay informed and consult healthcare professionals before considering any changes to wellness routines. Join our quest to educate the providers and patients about the impact of the endocannabinoid system by clicking the link in our bio and reading up on the various studies covering CBG. https://lnkd.in/gXymcpUX #CBG #parkinsons #endocannabinoidsystem #cannabigerol #formula30a

We are proud to share our original research article now in press in the Journal of Cardiac Failure, the results of our collaborative Phase I investigation into nebulized milrinone, which has some unique practical advantages to our current dependence on IV milrinone when supporting patients with advanced heart failure. We demonstrated pharmacokinetics, safety, and early hints of equivalent efficacy in improving hemodynamics for candidate patients. Rob Mentz Anuradha (Anu) Lala-Trindade (Lala) JCF (J Card Fail) https://lnkd.in/gGBabVAN

Today, we announced positive interim data from our ongoing Phase 2 trial evaluating the safety and efficacy of our product candidate in people with #ChronicNeutropenia (CN). We also announced that we’ve started screening patients for enrollment into our pivotal Phase 3 trial, the 4WARD study, to evaluate our product candidate in people with congenital, acquired primary autoimmune, or idiopathic CN.   We’re hosting a webinar today at 8:00 am ET and will detail the interim results, feature clinical experts in the treatment of CN, and discuss the 4WARD study.   Learn more here: https://lnkd.in/eaDtEtT6 #Progress4Patients 

350 million people worldwide struggle with vision loss due to retinal disorders, yet there are few available treatments for most #RetinalDiseases. At Johnson & Johnson, we dare to envision a world without blindness. That’s why we’re pioneering investigational #GeneTherapies that have the potential to positively impact patients, transform lives, and restore and preserve millions of people’s sight: https://lnkd.in/eQPeKaBz

Very interesting read. The versatility of using light to help the body heal many conditions is intriguing & positive now & into the future.

Enrollment in our Phase 2 DAZALS clinical trial studying amyotrophic lateral sclerosis (ALS) has closed.    Learn more about the trial here: https://lnkd.in/gZS3BRDg   #ALS #ClinicalTrial #CortisolModulation

(4/9) PI3Kα-Driven Vascular Malformations is the first of two programs in #geneticdisease that we unveiled today. #Vascularmalformations are a series of rare syndromes that occur due to atypical development of lymphatic and/or blood vessels, of which mutant PI3Kα is the most common driver. There are over ~170,000 patients with PI3Kα-driven vascular malformations in the U.S. We believe our mutant-selective PI3Kα inhibitor, RLY-2608, provides the opportunity for greater target coverage, leading to the potential for improved efficacy and better chronic tolerability for these patients. We plan to initiate clinical development in Q1 2025.

In patients with primary hyperparathyroidism, first-line F18-choline PET/CT is a suitable and safe replacement for MIBI SPECT/CT, finds randomized clinical trial. https://ja.ma/4c6v0Hx